Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

NUWE 10.23.2024

Full Press ReleaseSEC FilingsOur NUWE Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy
  • 12.19.2024 - Nuwellis Regains Compliance with Nasdaq Listing Requirements
  • 11.11.2024 - Nuwellis, Inc Third Quarter 2024 Earnings

Recent Filings

  • 12.20.2024 - EFFECT Notice of Effectiveness
  • 12.20.2024 - 424B3 Prospectus [Rule 424(b)(3)]
  • 12.19.2024 - S-1/A General form for registration of securities under the Securities Act of 1933

MINNEAPOLIS,Oct. 23, 2024(GLOBE NEWSWIRE) --Nuwellis, Inc.(Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 onMonday, November 11, 2024. Nuwellis will host a conference call and webcast at9:00 AM ETto discuss its financial results and provide a general business update.

To access the live webcast, please visit the Investors page of the Nuwellis website athttps://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-445-7795 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ3. An audio archive of the webcast will be available following the call on the Investors page athttps://ir.nuwellis.com.

About Nuwellis

Nuwellis, Inc.(Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered inMinneapolis, with a wholly owned subsidiary inIreland. For more information visitir.nuwellis.comor visit us onLinkedInorX.

About the Aquadex SmartFlow® System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

CONTACTS

INVESTORS:Vivian CervantesGilmartin Group LLCir@nuwellis.com

Primary Logo

Source: Nuwellis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com